Consensus Centessa Pharmaceuticals plc

Equities

CNTA

US1523091007

Market Closed - Nasdaq Other stock markets 21:00:00 29/04/2024 BST			5-day change	1st Jan Change
9.29 ^USD	+4.15%		-7.10%	+16.71%

04-24	Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Amid Earnings Deluge	MT
04-24	Centessa Pharmaceuticals Prices Equity Offering at $9.25 Per ADS	MT

Evolution of the average Target Price on Centessa Pharmaceuticals plc

Price target over the last 5 years

History of analyst recommendation changes

94f1a16c867142cd0f076beff47e.-5Fe0mD9zjX7b5aIojsBWDKENzs5Vw5kwSvYjFb8En8.mcgolxWcjGrIOafdkVBADnS2Bkt6Z1sM8Bqh6WKwaE6_og2fKa-ldJ5a8Q~909dbb2140eadf63700b054655844f1a

Analyst Recommendations on Centessa Pharmaceuticals plc

Morgan Stanley Upgrades Centessa Pharmaceuticals to Equalweight From Underweight, Doubles Price Target to $8 From $4 on 'Encouraging' Preclinical Data on Narcolepsy Treatment Candidate	26/10/23	MT
Guggenheim Adjusts Price Target on Centessa Pharmaceuticals to $10 From $9, Maintains Buy Rating	15/08/23	MT
Goldman Sachs Adjusts Price Target on Centessa Pharmaceuticals to $5 From $4.50, Maintains Neutral Rating	15/08/23	MT
BMO Capital Adjusts Centessa Pharmaceuticals Price Target to $15 From $11, Maintains Outperform Rating	25/07/23	MT
Evercore ISI Initiates Centessa Pharmaceuticals at Outperform Rating	21/06/23	MT
Guggenheim Initiates Centessa Pharmaceuticals at Buy With $9 Price Target	12/06/23	MT
SVB Securities Initiates Centessa Pharmaceuticals at Outperform With $6 Price Target	17/03/23	MT
Morgan Stanley Adjusts Price Target on Centessa Pharmaceuticals to $4 From $5, Maintains Underweight Rating	24/01/23	MT
Morgan Stanley Double Downgrades Centessa Pharmaceuticals to Underweight From Overweight, Adjusts Price Target to $5 From $10	12/08/22	MT
BMO Capital Adjusts Centessa Pharmaceuticals' Price Target to $11 from $19, Keeps Outperform Rating	11/08/22	MT
Goldman Sachs Adjusts Centessa Pharmaceuticals' Price Target to $4 From $5, Keeps Neutral Rating	11/08/22	MT
Morgan Stanley Adjusts Price Target for Centessa Pharmaceuticals to $10 From $15, Maintains Overweight Rating	14/07/22	MT
BMO Capital Starts Centessa Pharmaceuticals at Outperform With $19 Price Target	17/06/22	MT
Goldman Sachs Adjusts Centessa Pharmaceuticals' Price Target to $8 from $12, Keeps Neutral Rating	24/05/22	MT
Morgan Stanley Adjusts Centessa Pharmaceuticals Price Target to $15 From $19, Maintains Overweight Rating	24/05/22	MT
Morgan Stanley Trims Centessa Pharmaceuticals Price Target to $19 From $20, Maintains Overweight Rating	05/04/22	MT
Goldman Sachs Starts Centessa Pharmaceuticals at Neutral, Maintains Price Target at $12	11/02/22	MT
Morgan Stanley Adjusts Centessa Pharmaceuticals' Price Target to $20 from $37, Keeps Overweight Rating	01/02/22	MT
CENTESSA PHARMACEUTICALS : Jefferies Starts Centessa Pharmaceuticals at Buy With $35 Price Target	22/06/21	MT
CENTESSA PHARMACEUTICALS : Morgan Stanley Starts Centessa Pharmaceuticals at Overweight With $37 Price Target	22/06/21	MT
CENTESSA PHARMACEUTICALS : Goldman Sachs Starts Centessa Pharmaceuticals at Buy With $42 Price Target	22/06/21	MT